News

Public · Published

Canaccord Genuity maintains Hinge Health at Buy, raises price target to $134 from $105

Canaccord Genuity kept a Buy rating on Hinge Health and raised its price target to $134 from $105, a 27.6% increase. The new target implies 16.0% upside from the November 2 close of $115.48.

Published:

Updated:

What happened

Canaccord Genuity kept a Buy rating on Hinge Health and raised its price target to $134 from $105, a 27.6% increase. The new target implies 16.0% upside from the November 2 close of $115.48.

Confirmed

Global impact / market context

A higher price target signals that this analyst expects more share price gain ahead, which can draw buyer interest and support the stock. It also helps investors judge how the company's revenue and costs are viewed relative to peers.

Analyst inference

Other recent analyst targets for Hinge Health range from $110 to $140, showing broad positive views but some disagreement on the size of upside. That spread means investor positioning can shift as new estimates or company results arrive.

Analyst inference

What to watch

  1. Watch whether the stock trades closer to the $134 target or the November 2 close of $115.48, as the gap shows how much upside buyers still expect. Confirmed
  2. Track any new analyst notes after this change to see whether other firms also raise their targets, which would suggest growing confidence in the company. Proposed
  3. Follow Hinge Health's next revenue and cost updates, since weaker profit or higher spending could make analysts lower targets and pressure the shares. Analyst inference

Evidence

  • Original source link unavailable